Will the FDA approve Senseonics?
The US Food and Drug Administration (FDA) has approved the use of Senseonics’ Eversense E3 continuous glucose monitoring (CGM) system for periods of up to six months. The device uses sacrificial boronic acid (SBA) technology and is claimed to be the first and only long-term implantable CGM in the world.
Why did Senseonics drop?
What happened. Shares of Senseonics Holdings (SENS 11.88%) were sinking 14.3% as of 3:12 p.m. EDT on Thursday. The big drop came after the medical technology company announced the pricing of a public offering of its stock.
When can we expect FDA approval for Senseonics?
Back in 2020, Senseonics expected to win approval in the first quarter of 2021 and bring Eversense E3 to market shortly thereafter. However, the timeline slipped throughout last year. Senseonics now has its long-sought approval and a label that analysts at Craig-Hallum said matches their expectations.
What kind of Company is Senseonics?
medical technology company
Senseonics Holdings, Inc. operates as a medical technology company. The Company focuses on the design, development, and commercialization of glucose monitoring systems. Senseonics Holdings conducts business in the United States.
What is happening with Senseonics?
Senseonics Holdings (SENS) Beats Q4 Earnings and Revenue Estimates. Senseonics (SENS) delivered earnings and revenue surprises of 133.33% and 0.20%, respectively, for the quarter ended December 2021.
Is Senseonics a good investment?
Senseonics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Should I sell Senseonics?
Senseonics Holdings, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of SENS, demonstrate its potential to underperform the market. It currently has a Growth Score of F.
How high can Senseonics go?
The 3 analysts offering 12-month price forecasts for Senseonics Holdings Inc have a median target of 2.50, with a high estimate of 6.00 and a low estimate of 0.80.
Will Senseonics go up?
The 3 analysts offering 12-month price forecasts for Senseonics Holdings Inc have a median target of 2.50, with a high estimate of 6.00 and a low estimate of 0.80. The median estimate represents a +128.31% increase from the last price of 1.10.
What is the future of Senseonics?
The 3 analysts offering 12-month price forecasts for Senseonics Holdings Inc have a median target of 2.50, with a high estimate of 6.00 and a low estimate of 0.80. The median estimate represents a +112.77% increase from the last price of 1.18.
Is Senseonics overvalued?
The stock of Senseonics Holdings (AMEX:SENS, 30-year Financials) is believed to be significantly overvalued, according to GuruFocus Value calculation.